Compare OSPN & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | CGEM |
|---|---|---|
| Founded | 1991 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 946.7M | 999.4M |
| IPO Year | 2000 | 2020 |
| Metric | OSPN | CGEM |
|---|---|---|
| Price | $22.57 | $9.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $23.50 | ★ $34.70 |
| AVG Volume (30 Days) | ★ 876.8K | 792.7K |
| Earning Date | 10-29-2026 | 11-10-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ 28.77 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $243,180,000.00 | N/A |
| Revenue This Year | $5.28 | N/A |
| Revenue Next Year | $2.44 | N/A |
| P/E Ratio | $33.63 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.07 | $8.47 |
| 52 Week High | $27.45 | $23.19 |
| Indicator | OSPN | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 56.88 | 26.57 |
| Support Level | $21.29 | N/A |
| Resistance Level | $27.45 | $16.31 |
| Average True Range (ATR) | 1.12 | 1.22 |
| MACD | -0.16 | -0.27 |
| Stochastic Oscillator | 27.78 | 5.18 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.